{'fraction_non_alphanumeric': 0.028918590522478735, 'fraction_numerical': 0.015795868772782502, 'mean_word_length': 5.070796460176991, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Profound thrombocytopenia related with tirofiban: Will it be enough to only stop medicine?

GpIIb/IIIa receptor inhibitors (abciximab, eptifibatide, and tirofiban) which are used to treat the patients with acute coronary syndrome (ACS) cause thrombocytopenia with or without bleeding. The incidence of thrombocytopenia during the clinical use of tirofiban which is given to the patient with ACS ranges from 1% to 2% [1]. On the other hand, the incidence of severe thrombocytopenia ranges from 1% to 5% [2]. We have presented a profound-severe thrombocytopenia case which developed 24 hours after the tirofiban infusion and was treated with intravenous immunoglobulin (IVIG). In an 87-year-old female patient, coronary angiography was performed after the patient was diagnosed with ACS who was admitted to the emergency service with the complaint of chest pain. Percutaneous coronary angioplasty and stent placement to the right coronary artery were performed. The patient was treated with aspirin and beta blocker; 5000 IU, IV bolus of unfractionated heparin (UFH) followed by an UFH infusion of 1000 IU/hour and tirofiban 0.4 mg/kg/min for 30 min followed by 0.1 mg/kg/min IV were started. When the patient was first admitted, her hemoglobin level was 10.5 g/dl, white blood cell level was 13 10 /uL, platelet level was 242 10 /uL, PTaPTT, and fibrinogen levels were normal. When it was found out that her aPTT level was 115 at the 12th hour, heparin infusion, was stopped. Because the patient had active melena, the patient’s blood count showed that her hemoglobin level was 8.5 g/dl, and platelet level was 3 10 /uL. Tirofiban infusion which she had been taking for 24 hours was stopped because of the gastrointestinal system (GIS) bleeding and thrombocytopenia. The patient was examined by the hematology department because of the thrombocytopenia. The physical examination results of the patient showed the presence of active hematemesis in nasogastric catheter and ecchymosis in injection area. Platelet count was confirmed by peripheral blood smear. Peripheral blood smear showed the presence of one platelet in each area, platelet clumping, and fragmentation in erythrocyte were not observed, pathologic cell was not found out. PT-aPTT, fibrinogen, and D-dimmer tests performed for disseminate intravascular coagulopathy were normal. Because the patient had an active GIS bleeding problem, she received erythrocyte and platelet suspension transfusion, and was started with 400 mg/kg/day IVIG. One day after the tirofiban was stopped and at the 12th hour of IVIG treatment her platelet count was found as 26 10 /uL. On the third day of the IVIG treatment, thrombocyte levels increased up to 152 10 /uL. Platelet counts variance after the tirofiban was stopped and during the IVIG treatment was given in Figure 1. After the signs of GIS bleeding disappeared, the patient was discharged taking antiaggregant, and antianginal. Clinical observations did not show any problem concerning thrombocytopenia or bleeding. Thrombocytopenia mechanism, caused by GpIIb/IIIa receptor inhibitors, could not be understood completely. This may result from the antiplatelet antibodies caused by the use of medicine [3]. Another hypothesis is the antibodies, produced naturally against the platelet neoepitopes during the use of GpIIb/IIIa receptor inhibitors [4]. When the thrombocytopenia develops in the patients treated with GpII/bIIIa receptor inhibitors and heparin, differential diagnosis should be applied to search for other reasons. Peripheral blood smear should be examined in terms of pseudothrombocytopenia and clumping platelets should be verified to confirm EDTA phenomenon. In our case, clumping platelets were not observed in peripheral blood smear, one platelet was observed in each area when it was examined by microscope. The platelet count was presented to be lower in blood samples anticoagulated with citrate. Lower platelet count was confirmed by these tests results. Since, our patient used heparin, heparin induced thrombocytopenia (HIT) was among the differential diagnosis. To confirm the diagnosis,